scispace - formally typeset
U

Uwe Fuchs

Researcher at Ruhr University Bochum

Publications -  49
Citations -  1060

Uwe Fuchs is an academic researcher from Ruhr University Bochum. The author has contributed to research in topics: Heart transplantation & Transplantation. The author has an hindex of 14, co-authored 49 publications receiving 933 citations. Previous affiliations of Uwe Fuchs include Heart and Diabetes Center North Rhine-Westphalia.

Papers
More filters
Journal ArticleDOI

Clinical Outcome of Patients With Deep Sternal Wound Infection Managed by Vacuum-Assisted Closure Compared to Conventional Therapy With Open Packing: A Retrospective Analysis

TL;DR: A retrospective analysis could demonstrate that the vacuum technique improves the medical outcome of patients with mediastinitis compared with the conventional technique of open packing.
Journal ArticleDOI

Poor outcome in end-stage heart failure patients with low circulating calcitriol levels.

TL;DR: Vitamin D receptor knockout mice develop typical signs of congestive heart failure and low concentrations of the vitamin D hormone calcitriol are found in stable CHF patients.
Journal ArticleDOI

Donor-Derived Cell-Free DNA Is a Novel Universal Biomarker for Allograft Rejection in Solid Organ Transplantation.

TL;DR: The quantification of GcfDNA has the potential to detect rejection episodes at early stages, when other means of diagnosis are not effective and the method's noninvasiveness enables the monitoring recipients at intervals that are desired to catch rejections at early actionable stages to prevent full-blown rejection.
Journal ArticleDOI

Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients.

TL;DR: It is demonstrated that in heart transplant recipients with renal insufficiency the introduction of 1.5 mg/d EVL in combination with a reduced TAC dose is effective in preventing cardiac rejections and has less adverse effects on lipid metabolism than the usually prescribed SRL dose, whereas both therapy regimens are not associated with major haematological side‐effects.